Expression and Nuclear Localization of ErbB3 in Prostate Cancer
暂无分享,去创建一个
I. H. Koumakpayi | J. Diallo | C. Le Page | L. Lessard | M. Gleave | L. Bégin | A. Mes-Masson | F. Saad | I. Koumakpayi
[1] M. Kraus,et al. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[2] I. Ellis,et al. Production and characterization of a polyclonal antibody to the c‐erbB‐3 protein: Examination of c‐erbB‐3 protein expression in adenocarcinomas , 1992, The Journal of pathology.
[3] N. Lemoine,et al. Expression of the c-erbB-3 protein in normal human adult and fetal tissues. , 1992, Oncogene.
[4] W. Grizzle,et al. Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. , 1994, Journal of the National Cancer Institute.
[5] Y. Yoshihama,et al. Prognostic significance of ERRB3 overexpression in oral squamous cell carcinoma , 1995 .
[6] Prognostic significance of ERBB3 overexpression in oral squamous cell carcinoma. , 1995, Cancer letters.
[7] A. Mes-Masson,et al. Overexpression of her-2/neu in human prostate cancer and benign hyperplasia. , 1996, Cancer letters.
[8] Gullick Wj. The c-erbB3/HER3 receptor in human cancer. , 1996 .
[9] W. Gullick. The c-erbB3/HER3 receptor in human cancer. , 1996, Cancer surveys.
[10] J. Rodrigo,et al. Amplification of ERBB oncogenes in squamous cell carcinomas of the head and neck , 1996 .
[11] J. Rhim,et al. ErbB kinases and NDF signaling in human prostate cancer cells , 1997, Oncogene.
[12] Mark A. Stephenson,et al. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[13] M. Melhem,et al. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. , 1997, The cancer journal from Scientific American.
[14] W. Gullick,et al. A potential autocrine loop between heregulin-alpha and erbB-3 receptor in human prostatic adenocarcinoma. , 1997, British journal of urology.
[15] W. Russell,et al. Hepatic expression of ErbB3 is repressed by insulin in a pathway sensitive to PI-3 kinase inhibitors. , 1997, Endocrinology.
[16] Yosef Yarden,et al. Neuregulins and Their Receptors: A Versatile Signaling Module in Organogenesis and Oncogenesis , 1997, Neuron.
[17] Kuala Lumpur Malaysia,et al. Expression of c-erbB3 protein in primary breast carcinomas. , 1998, British Journal of Cancer.
[18] H. Kung,et al. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells , 1998, Nature.
[19] W. Gullick,et al. Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 Growth Factor Receptors and Their Ligands, Neuregulin-1 α, Neuregulin-1 β, and Betacellulin, in Normal Endometrium and Endometrial Cancer , 1999 .
[20] W. Gullick,et al. Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta, and betacellulin, in normal endometrium and endometrial cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] D. Barnes,et al. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. , 2000, Cancer research.
[22] J. Manola,et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. , 2000, Journal of the National Cancer Institute.
[23] H. Kishimoto,et al. Increased expression of c‐erbB‐3 protein and proliferating cell nuclear antigen during development of verrucous carcinoma of the oral mucosa , 2000, Cancer.
[24] Monilola A. Olayioye,et al. The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.
[25] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[26] J. Hsuan,et al. EGF receptors as transcription factors: ridiculous or sublime? , 2001, Nature Cell Biology.
[27] R. Nicholson,et al. EGFR and cancer prognosis. , 2001, European journal of cancer.
[28] Y. Yarden. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.
[29] K. Makino,et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor , 2001, Nature Cell Biology.
[30] Localizing the EGF receptor , 2002, Nature Cell Biology.
[31] R. Autorino,et al. Expression of epidermal growth factor receptor (EGFR) correlates with disease relapse and progression to androgen-indepedence in human prostate cancer , 2002 .
[32] S. Coughlin,et al. A review of genetic polymorphisms and prostate cancer risk. , 2002, Annals of epidemiology.
[33] Y. Shang,et al. Formation of the androgen receptor transcription complex. , 2002, Molecular cell.
[34] Qianben Wang,et al. Repression of androgen receptor mediated transcription by the ErbB-3 binding protein, Ebp1 , 2002, Oncogene.
[35] Stefania Staibano,et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] F. Maurer,et al. The ErbB 2 ErbB 3 heterodimer functions as an oncogenic unit : ErbB 2 requires ErbB 3 to drive breast tumor cell proliferation , 2003, Nature Reviews. Cancer.
[37] J. D. de Vicente,et al. Expression of ErbB-3 and ErbB-4 protooncogene proteins in oral squamous cell carcinoma: a pilot study. , 2003, Medicina oral : organo oficial de la Sociedad Espanola de Medicina Oral y de la Academia Iberoamericana de Patologia y Medicina Bucal.
[38] L. Lessard,et al. NF-kappa B nuclear localization and its prognostic significance in prostate cancer. , 2003, BJU international.
[39] N. Hynes,et al. The ErbB receptors and their role in cancer progression. , 2003, Experimental cell research.
[40] J. R. Reeves,et al. Outcome and human epidermal growth factor receptor (HER) 1–4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling , 2004, Breast Cancer Research.
[41] M. Iacocca,et al. Human epidermal receptor-2 expression in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[42] L. Morrison,et al. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. , 2003, Cancer research.
[43] A. Iwamatsu,et al. Activation of ErbB3–PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas , 2003, Oncogene.
[44] F. Maurer,et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[45] G. Carpenter,et al. ErbB-4: mechanism of action and biology. , 2003, Experimental cell research.
[46] L. Lessard,et al. NF‐κB nuclear localization and its prognostic significance in prostate cancer , 2003 .
[47] S. Fosså,et al. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence , 2004, British Journal of Cancer.
[48] T. Giordano,et al. Cell Surface Expression of Epidermal Growth Factor Receptor and Her-2 with Nuclear Expression of Her-4 in Primary Osteosarcoma , 2004, Cancer Research.
[49] M. Hung,et al. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. , 2004, Cancer cell.
[50] G. Devries,et al. Localization of neuregulin isoforms and erbB receptors in myelinating glial cells , 2004, Glia.
[51] J. Kern,et al. Autocrine activation of ErbB2/ErbB3 receptor complex by NRG-1 in non-small cell lung cancer cell lines. , 2004, Lung cancer.
[52] W. Gullick,et al. The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer , 2004, Breast Cancer Research and Treatment.
[53] Ingo K Mellinghoff,et al. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. , 2004, Cancer cell.
[54] G. Stamp,et al. Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. , 2004, Neoplasia.
[55] H. Lane,et al. ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors , 2005, Nature Reviews Cancer.
[56] M. Hung,et al. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. , 2005, Cancer research.
[57] J. Bartlett,et al. Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer , 2005, The Journal of pathology.
[58] A. Jemal,et al. Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.
[59] A. Hamburger,et al. Specificity and heregulin regulation of Ebp1 (ErbB3 binding protein 1) mediated repression of androgen receptor signalling , 2004, British Journal of Cancer.
[60] F. S. French,et al. Heregulin-Induced Activation of HER2 and HER3 Increases Androgen Receptor Transactivation and CWR-R1 Human Recurrent Prostate Cancer Cell Growth , 2005, Clinical Cancer Research.
[61] C. Le Page,et al. EGFR and Her‐2 regulate the constitutive activation of NF‐kappaB in PC‐3 prostate cancer cells , 2005, The Prostate.
[62] Y. Oshika,et al. P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.
[63] J. Bartlett,et al. The Role of HER1-HER4 and EGFRvIII in Hormone-Refractory Prostate Cancer , 2006, Clinical Cancer Research.